Skip to main content
Premium Trial:

Request an Annual Quote

NIH Negotiating with Celera for Access to Celera s Database

NEW YORK, Jan 12 - A new chapter in the storied and stormy relationship between the National Institutes of Health and Celera Genomics has apparently begun, as NIH officials are now negotiating with Celera for terms of access to its genome database, a NIH spokesman told GenomeWeb Friday.
 
" Negotiations are underway," the spokesman said, separately confirming a report published in Science 's online news service Friday morning.  Science  reported that a number of NIH scientists had requested subscriptions to Celera's database, and that a group of National Cancer Institute Scientists had evaluated Celera's database and found it useful.
 
If NIH scientists do gain access to Celera's database - at the price of between $7,000 and $15,000 per head - they would effectively be paying for a souped-up version of their own Human Genome Project research published in GenBank, plus Celera's own sequencing research.
 
Some scientists at the NIH are uncomfortable with this arrangement, but many NIH officials don't see any problem in it, according to Science . " We do it all the time" with scientific journals, Steven Hyman, director of the National Institute of Mental Health, told Science . " We pay for the research, we pay for publication costs, and then we pay for the journal subscription for our scientists. We do it without complaining..."  
 

A Celera Genomics spokesperson said the company had no comment on the matter. Officials at the National Human Genome Research Institute had no immediate comment, but expect to make an announcement next week.
 
 
The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more